Commentary|Articles|March 16, 2026

Expert Q&A: Key Counseling Points for FDA-Approved Somapacitan in Growth Disorders

Author(s)Nicky Kelepouris, MD, Luke Halpern, Associate Editor

Novo Nordisk's Nicky Kelepouris, MD, discusses the REAL8 trial, the expanded pediatric indications for once-weekly somapacitan, and the pharmacist's role in supporting families navigating long-term growth hormone therapy.

In an interview with Pharmacy Times, Nicky Kelepouris, MD, United States medical lead of rare endocrine disorders at Novo Nordisk, discussed the REAL8 (NCT05330325) trial and the expanded FDA pediatric indications for somapacitan-beco (Sogroya; Novo Nordisk), the first and only once-weekly, long-acting growth hormone approved for 3 additional pediatric growth disorders: short stature born small for gestational age (SGA), idiopathic short stature (ISS), and Noonan Syndrome (NS).